Phase 3 N=46 Lamotrigine in Reducing Psychologic Side-Effect of Perioperative Ketamine
Reducing Psychological Side Effects of Ketamine
Primary: Psychologic Side-effects — 4; 4 score on a scale — p=0.08
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=171 Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Familial Adenomatous Polyposis
Primary: Number of Subjects With Any FAP-related Event. — 18; 23; 22; 2 Participants — p=0.1210
Phase 3 N=816 Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon
Malaria
Primary: Cure Rate on Day 28 — 197; 603 Participants — p=>0.05
Phase 3 N=91 Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial
Thoracic Diseases · Postoperative Pain · Opioid Use
Primary: Average Daily In-Hospital Use of Opioids — 40; 45 Oral Morphine Equivalent per Day
Phase 3 N=422 The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure
Sepsis · Delirium · Impaired Cognition
Primary: Delirium/Coma Free Days (DCFDs) — 8; 7.5 days
Phase 3 N=203 Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
Extragonadal Germ Cell Tumor · Teratoma · Testicular Germ Cell Tumor
Primary: Progression-free Survival Rate After 1 Course of Treatment — 48; 59 percentage of participants — p=0.05
Phase 3 N=564 A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
Essential Hypertension
Primary: Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs) and Death — 57; 54; 255; 0 Participants
Phase 3 N=942 Phase 3 Study of Dexpramipexole in ALS
Amyotrophic Lateral Sclerosis
Primary: Composite Assessment of Function and Survival (CAFS) at 12 Months — 438.84; 441.76 units on a scale — p=0.8568
Phase 3 N=82 Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
Pre Diabetes · Polycystic Ovary Syndrome · Obesity Android
Primary: Absolute Body Weight (BW) — 104.7; 117.9 kilogram — p=<0.002
Phase 3 N=200 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults
Dengue Fever
Primary: Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120 — 557.4; 2047.4; 131.8; 119.6 titer
Phase 3 N=331 Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis
Moderate to Severe Chronic Plaque-type Psoriasis
Primary: Percentage of Subjects Who Achieve 90% or Greater Reduction in Psoriasis Area and Severity Index (PASI) Score - Week 16 (Full Analysis Set) — 121; 92 Participants…
Phase 3 N=285 JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear' (0) or 'Almost Clear' (1) and ≥2 Points Improvement From Baseline at Week…
Phase 3 N=386 Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 24 — -0.74; -0.82 percentage of HbA1c
Phase 3 N=89 A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)
Advanced Parkinson's Disease
Primary: Change From Baseline to Week 26 in the NMSS Total Score — -23.83; -32.04 score on a scale — p=0.410
Phase 3 N=55 Open Label Extension to Bridging Study CTBM100C2303
Pseudomonas Aeruginosa · Cystic Fibrosis
Primary: Percentage of Participants With Adverse Events (AEs) — 47.3 percentage of participants